RCA HGB-208 Pushback Seen as 'Modest Stumble', Roth Capital Says

Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating and $192 price target on bluebird bio (NASDAQ: BLUE) following news after the close the RAC recommendation on the HGB-208 study (pediatrics, <12 years old) was to delay enrollment in the U.S.

Importantly, this has no effect on any other programs, or conditional approval in the EU, Chattopadhyay. However, management expects to aggressively pursue pediatric enrollment in the EU and in the U.S., let patients and IRB's decide on -208 study participation.

"A modest stumble, but given the complexity/risks of the procedure, understandable," the analyst comments.

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $186.63 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• DA Davidson Reiterates Neutral Rating on Timken (TKR)
• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential